View in EDS

Every Other Day or Once a Week: Long-term Oncological Outcomes in the Phase 2 PATRIOT Trial of Prostate Stereotactic Ablative Body Radiotherapy.

Saved in:
Bibliographic Details
Title: Every Other Day or Once a Week: Long-term Oncological Outcomes in the Phase 2 PATRIOT Trial of Prostate Stereotactic Ablative Body Radiotherapy.
Authors: Ong WL; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Canada; Alfred Health Radiation Oncology, Monash University, Melbourne, Australia., Quon H; Tom Baker Cancer Centre, Calgary, Canada., Ong A; CancerCare Manitoba, Winnipeg, Canada., Cheung P; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Canada., Chu W; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Canada., Chung H; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Canada., Vesprini D; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Canada., Chowdhury A; CancerCare Manitoba, Winnipeg, Canada., Panjwani D; BC Cancer Agency, Abbotsford, Canada., Alayed Y; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Canada; Oncology Center, King Saud University, Riyadh, Saudi Arabia; Radiation Oncology Unit, Department of Medicine, College of Medicine and College of Medicine Research Center, King Saud University, Riyadh, Saudi Arabia., Pang G; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Canada., Korol R; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Canada., Davidson M; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Canada., Ravi A; Department of Radiation Oncology, University of Toronto, Toronto, Canada; Molli Surgical, Toronto, Canada., McCurdy B; CancerCare Manitoba, Winnipeg, Canada., Zhang L; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada., Kulasingham-Poon M; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada., Mamedov A; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada., Deabreu A; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada., Loblaw A; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Canada; Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Canada. Electronic address: andrew.loblaw@sunnybrook.ca.
Source: European urology oncology [Eur Urol Oncol] 2025 Aug; Vol. 8 (4), pp. 909-913. Date of Electronic Publication: 2025 Apr 26.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101724904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2588-9311 (Electronic) Linking ISSN: 25889311 NLM ISO Abbreviation: Eur Urol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2588-9311
DOI:10.1016/j.euo.2025.03.011